Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 30, 2002
Business Overview: The Company operates two primary segments: Healthcare Distribution (dental, medical, and international markets) and Technology (practice management software). The reporting period reflects the adoption of new accounting standards (FAS 142) regarding goodwill.
Key Financial Metrics
| Metric (in thousands) | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $647,093 | $593,895 |
| Gross Profit | $178,390 | $159,357 |
| Gross Margin | 27.6% | 26.8% |
| Operating Income | $35,198 | $27,583 |
| Net Income | $19,730 | $14,132 |
| Diluted EPS | $0.45 | $0.33 |
| Cash and Equivalents (End of Period) | $93,421 | $38,112 |
| Total Debt (Current + Long-term) | $249,211 | N/A |
| Net Cash Used in Operating Activities | $(38,786) | $(12,091) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9.0% ($53.2 million), driven primarily by the Healthcare Distribution segment (8.9% increase). Dental sales rose 9.7% and Medical sales rose 10.9% due to increased account penetration.
- Profitability: Operating income increased 27.6% to $35.2 million. Net income rose 39.6% to $19.7 million. A significant factor was the elimination of goodwill amortization expense ($2.9 million) following the adoption of FAS 142.
- Cash Flow: Operating cash flow turned negative at $(38.8) million, compared to $(12.1) million in the prior year. This was primarily due to a $64.9 million decrease in accounts payable and accruals, attributed to vendor payments for year-end inventory buy-ins.
- Investing Activities: Significant cash outflow of $56.5 million, driven by $28.2 million in business acquisitions (including earnout payments) and $17.6 million in capital expenditures (including a corporate headquarters building).
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects to invest over $50.0 million in 2002 to modernize facilities and computer infrastructure.
- Liquidity: On May 2, 2002, the Company renewed and increased its revolving credit facility to $200.0 million (four-year term). As of March 30, 2002, the facility was unutilized. Management believes current cash and credit availability are sufficient for foreseeable needs.
- Seasonality: The business is seasonal, with Q1 typically lower due to prior quarter purchasing patterns. Q4 is generally the strongest quarter.
- Legal Contingencies:
- Product Liability: Defendant in approximately 74 cases, including 59 involving latex glove allergies and 9 involving "Phen/fen" drugs. The Company expects indemnification from manufacturers but notes no assurance of coverage sufficiency.
- Class Action: Pending appeal in the Texas Supreme Court regarding a class action suit involving practice management software (Easy Dental). A trial is stayed pending the Supreme Court's decision.
- Market Risks: Exposure to foreign currency fluctuations, consolidation of healthcare practitioners, and competitive pressures from e-commerce solutions.
Investor Verification Checklist
- Working Capital Trends: Verify the sustainability of the $64.9 million reduction in accounts payable and its impact on future operating cash flows.
- Acquisition Integration: Assess the performance of recent acquisitions and the $22.1 million earnout payment made during the quarter.
- Legal Exposure: Monitor the outcome of the Texas Supreme Court appeal regarding the software class action and the status of indemnification for latex glove and Phen/fen litigation.
- Goodwill Impairment: Watch for the results of the transitional goodwill impairment test required by FAS 142, expected to be completed in Q2 2002.
- Capital Allocation: Track the execution of the planned $50+ million capital expenditure program for facility and IT modernization.